Want to see FR:ALMDT full AI Analyst Report?
ALMDT Stock Chart & Stats
€4.06
€0.03(0.63%)
At close: 4:00 PM EDT
€4.06
€0.03(0.63%)
Day’s Range― - ―
52-Week Range€1.79 - €7.27
Previous CloseN/A
Volume15.31K
Average Volume (3M)465.96K
Market Cap
€198.00M
Enterprise Value€180.92
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding49,048,060
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.44
Revenue Forecast (FY)€25.42M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendSustained top-line growth, accelerating to +21.5% in 2025 after +3.2% in 2024, indicates growing market traction for imaging services and software. Over 2–6 months this supports durable revenue runway from clinical-trial demand rather than a one-off spike.
Diversified Biopharma And Software Revenue ModelThe company generates revenues from recurring software/licensing and per-trial imaging services for pharma/CROs. This mix provides multiple durable monetization pathways—project-based trial fees plus potential subscription SaaS—reducing reliance on a single revenue source.
Specialized Oncology AI Imaging PlatformA focused AI imaging platform for oncology creates a technical moat tied to specialized analytics and biomarker extraction. This domain expertise and data footprint support stickiness with trial sponsors and long-term licensing opportunities as imaging biomarkers gain regulatory importance.
Bears Say
Persistent UnprofitabilityOngoing operating and net losses mean internal earnings cannot fund growth or R&D. Over several months this raises structural financing risk, likely requiring dilution or debt, which can constrain long-term strategic investments and limit operational flexibility.
Negative Shareholders' EquityA negative equity position signals accumulated losses that weaken the capital base and reduce shock absorbers for adverse events. Structurally, this limits borrowing capacity and heightens dependence on external financing, raising long-term solvency concerns.
Consistent Negative Operating Cash FlowPersistent negative operating cash flow indicates the core business does not generate cash, requiring recurrent funding to sustain operations. This undermines the company’s ability to self-fund scaling, increases refinancing risk, and can pressure strategic initiatives over time.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.79 and its highest was €7.27 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €198.00M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 75 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 49,048,060 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in FR:ALMDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―